MDxHealth S.A.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $57.2M
- Price
- $0.5999
- % Change (Daily % change from the live per-ticker quote feed.)
- +0.50%
- Volume
- 184.5K
About
MDxHealth SA is a commercial-stage precision diagnostics firm delivering specialized urologic solutions across the globe. Its international footprint includes the United States, various European nations such as the Netherlands, Belgium, Spain, Poland, Italy, and the wider European Union. The company's innovative genomic testing portfolio for prostate cancer comprises SelectMDx, a non-invasive urine test, and ConfirmMDx, an epigenetic diagnostic tool. These advanced offerings enable medical professionals to precisely identify clinically significant prostate cancer, thereby minimizing reliance on invasive procedures and their associated risks. Established in 2003, with its headquarters in Herstal, Belgium, the entity was formerly known as OncoMethylome Sciences SA until its renaming to MDxHealth SA in October 2010.
Quick stats
Shares outstanding95.4M
Computed float39.1M
Float / shares41.0%
Cash runway (months)28.6
Key info
SectorHealthcare
IndustryMedical - Diagnostics & Research
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001872529
Websitehttps://mdxhealth.com
AI Summary
AI-generated1/11
majormixedearnings
Mdxhealth Reports Second Quarter 2026 Financial Results
MDxHealth reported Q2 revenue of $27.2 million, up 16% year-over-year, and reaffirmed its 2026 revenue guidance of $110-115 million despite a widening net loss to $9.5 million driven by ExoDx integration costs.
The company completed the wind-down of its Resolve mdx business, with subsidiary Delta Laboratories executing an Assignment for the Benefit of Creditors to address liabilities, including a $10.4 million recoupment claim from Novitas Solutions.
To strengthen its balance sheet, MDxHealth closed a registered direct placement of 44 million shares at $0.454, raising $20 million in gross proceeds and boosting its pro-forma cash position to $39.2 million.
Red flags
- Net loss increased 36% over prior year period to $9.5 million
- Adjusted EBITDA turned negative to ($2.3) million from a positive $1.1 million in the prior year
- Delta Laboratories executed an Assignment for the Benefit of Creditors (bankruptcy/insolvency process)
- Novitas Solutions filed a $10.4 million recoupment claim against Delta Lab